Coming onto the international pharmaceutical, biotechnology and generics scene this month is an all new electronic publication, THE PHARMA LETTER (http://www.thepharmaletter.com), which will provide subscribers with daily authoritative news, business intelligence, patent news, comment and analysis for these sectors of the overall health care industry worldwide.

This is backed by a team of respected writers and overseas correspondents, with many years of experience in the field. The team is led by Barbara Obstoj, most recently Managing Editor of the Pharma Marketletter and previously founding editor of Scrip Pharmaceutical News.

The service also provides an extensive archive going back nearly 20 years, to research and recall background news and information.

News is identified by three categories;

PHARMACEUTICAL, which covers patent-protected prescription medicines, with news relating to drug makers, their financial performance, licensing, research and merger & acquisition activities. This also reports on health care markets, patent developments, legislation, product approvals and delays around the globe, backed by a massive archive from which developments in all these areas can be tracked.

BIOTECHNOLOGY, which looks at news relating to biotech companies, their financial performance, licensing, research and merger & acquisition activities. This also reports on health care markets, patent developments, legislation, product approvals and delays around the globe, backed by a massive archive from which developments in all these areas can be tracked. At this time of new legislation and activities in the area of “biosimilars: or “biogenerics” approvals, which have progressed more in Europe and are likely to impact the huge US market quite soon, watching this area will be an important aspect for subscribers.

GENERICS, the bane of the research-based pharmaceutical industry, are a very important aspect of the health care industry to monitor, as more and more governments around the world are pushing for their greater use in order to contain health care budgets, while the launch of copy products on patent expiry - and often even before this actually occurs - can wipe billions of dollars off drug makers’ revenues.

The Pharma Letter (http://www.thepharmaletter.com) will provide a searchable archive of 20 years Pharma and Biotech news news, a daily Pharma news round-up email, a business directory, job opportunities within the Pharma and biotech market, a Pharma press release service, an expert forum for Pharma and biotech news discussion and many more forthcoming features.

The Pharma Letter website (http://www.thepharmaletter.com), is powered by WORKSsitebuilder CMS (http://www.workssitebuilder.com), a leading content management solution (CMS) for the publishing sector.

-- Ends --

About WORKSsitebuilder:

WORKSsitebuilder has been developed with publishers in mind to meet the challenges that face the publishing industry.

- Take control of your website content & ongoing search engine optimisation
- Functions to attract, convert & retain subscribers
- Create, configure and manage online Trials & Subscriptions
- Build an interactive site community
- Generate additional online revenue


Contact:
Angus Phillipson
Director
http://www.WORKSsitebuilder.com

T: +44 (0)208 780 6350
mailto:angus@workssitebuilder.com
http://twitter.com/AngusPhillipson

Published on: 12:53PM on 15th September 2009